Safety and efficacy of first-line bevacizumab with FOLF fluoropyrimidines in metastatic colorectal cancer: the B

Annals of Oncology

20, 1842-1847

DOI: 10.1093/annonc/mdp233

Citation Report

#	Article	IF	Citations
2	Metastatic colorectal cancer: recent advances in its clinical management. Expert Review of Anticancer Therapy, 2009, 9, 1829-1847.	1.1	24
3	Current perspective: Bevacizumab in colorectal cancer â€“ A time for reappraisal?. European Journal of Cancer, 2009, 45, 2452-2461.	1.3	34
4	Bevacizumab-associated gastrointestinal perforation. Lancet Oncology, The, 2009, 10, 534-536.	5.1	10
5	Chemotherapy for the Elderly Patient With Colorectal Cancer. Cancer Journal (Sudbury, Mass), 2010, 16, 241-252.	1.0	18
6	Liver Resection Remains a Safe Procedure After Neoadjuvant Chemotherapy Including Bevacizumab. Annals of Surgery, 2010, 252, 124-130.	2.1	42
7	2010, 99, 2165-2171.	0.0	0
8	Current Progress in Targeted Therapy for Colorectal Cancer. Cancer Control, 2010, 17, 7-15.	0.7	57
9	Management of liver metastases from colorectal cancer. Clinical Journal of Gastroenterology, 2010, 3, 128-135.	0.4	2
10	Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. Clinical and Translational Oncology, 2010, 12, 533-542.	1.2	51
11	"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. BMC Cancer, 2010, 10, 567.	1.1	41
12	Bevacizumab toxicities and their management in ovarian cancer. Gynecologic Oncology, 2010, 117, 497-504.	0.6	91
13	The effects of bevacizumab on postoperative complications in patients undergoing colorectal and pancreatic cancer resection. Journal of Surgical Oncology, 2010, 102, 539-542.	0.8	7
14	The neoadjuvant therapy of colorectal hepatic metastases and the role of biologic sensitizing and resistance factors. Journal of Surgical Oncology, 2010, 102, 891-897.	0.8	9
15	Biologic modulation of chemotherapy in patients with hepatic colorectal metastases: The role of antiâ€VEGF and antiâ€EGFR antibodies. Journal of Surgical Oncology, 2010, 102, 937-945.	0.8	8
17	Antivascular Therapy for Epithelial Ovarian Cancer. Journal of Oncology, 2010, 2010, 1-16.	0.6	7
18	Using bevacizumab to treat metastatic cancer: UK consensus guidelines. British Journal of Hospital Medicine (London, England: 2005), 2010, 71, 670-678.	0.2	10
19	Chemotherapy for Colorectal Cancer. Journal of the Korean Medical Association, 2010, 53, 582.	0.1	4
20	Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials. Journal of Clinical Oncology, 2010, 28, 2280-2285.	0.8	400

#	Article	IF	Citations
21	Using bevacizumab with different chemotherapeutic regimens in metastatic colorectal cancer: balancing utility with low toxicity. Therapeutic Advances in Medical Oncology, 2010, 2, 309-317.	1.4	8
22	Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancerâ€"an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009. Annals of Oncology, 2010, 21, 1579-1584.	0.6	58
23	Aneurysm formation in an angiomyolipoma during bevacizumab combination therapy. Acta OncolÃ³gica, 2010, 49, 864-866.	0.8	3
24	Cardiovascular Safety of VEGF-Targeting Therapies: Current Evidence and Handling Strategies. Oncologist, 2010, 15, 683-694.	1.9	43
25	Stop and Go FOLFOX plus Bevacizumab Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer. Oncology, 2010, 79, 67-71.	0.9	12
26	Multigene Assays to Improve Assessment of Recurrence Risk and Benefit From Chemotherapy in Early-Stage Colon Cancer: Has the Time Finally Arrived, or Are We Still Stage Locked?. Journal of Clinical Oncology, 2010, 28, 3904-3907.	0.8	8
27	Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer. Oncology, 2010, 79, 118-128.	0.9	21
28	Metastatic Colorectal Cancer: From Improved Survival to Potential Cure. Oncology, 2010, 78, 237-248.	0.9	210
29	Antiangiogenic Therapy in Colorectal Cancer: Where Are We 5 Years Later?. Clinical Colorectal Cancer, 2010, 9, S7-S15.	1.0	6
30	Improving Response and Outcomes for Patients With Liver-Limited Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2010, 9, S36-S43.	1.0	3
31	ConsÃ©quences de la chimiothÃ©rapie sur la rÃ©section des mÃ©tastases hÃ©patiques dâ€™origine colorectale. Journal De Chirurgie ViscÃ©rale, 2010, 147, 255-264.	0.0	0
32	Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil, and leucovorin in patients with locally advanced rectal cancer. European Journal of Surgical Oncology, 2010, 36, 1061-1065.	0.5	67
35	The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer. Cancer Treatment Reviews, 2010, 36, S1-S10.	3.4	23
36	Chemotherapy: Metastatic Disease. , 2010, , 189-222.		0
37	Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncology, The, 2010, 11, 373-382.	5.1	114
38	Resection of colorectal liver metastases: only for younger patients?. Lancet Oncology, The, 2010, 11, 116.	5.1	1
39	Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncology, The, 2010, 11, 845-852.	5.1	234
41	Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Annals of Oncology, 2010, 21, 1152-1162.	0.6	154

#	Article	IF	Citations
42	Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. Journal of Experimental and Clinical Cancer Research, 2010, 29, 58.	3.5	46
43	Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors. Expert Opinion on Biological Therapy, 2011, 11, 1433-1445.	1.4	15
44	Late anastomotic colonic dehiscence due to antiangiogenic treatment, a specific drug-class complication requiring specific treatment: An example of pazopanib complication. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 135-139.	0.7	16
45	Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer, 2011, 11, 247.	1.1	69
46	Role of the Antiangiogenic Agent Bevacizumab in the Treatment of Elderly Patients with Metastatic Colorectal Cancer. Drugs and Aging, 2011, 28, 83-91.	1.3	2
47	Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104â€"A Randomized Trial of the German AIO CRC Study Group. Journal of Clinical Oncology, 2011, 29, 1050-1058.	0.8	99
48	Survival for Metastatic Colorectal Cancer in the Bevacizumab Era: A Population-based Analysis. Clinical Colorectal Cancer, 2011, 10, 97-101.	1.0	26
49	A Phase II Study of Oxaliplatin, Dose-intense Capecitabine, and High-dose Bevacizumab in the Treatment of Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2011, 10, 210-216.	1.0	10
50	Integration of Biologic Agents With Cytotoxic Chemotherapy in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2011, 10, 245-257.	1.0	20
51	Vascular endothelial growth factor inhibition: Conflicting roles in tumor growth. Cytokine, 2011, 53, 115-129.	1.4	17
52	Review: Incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer. European Journal of Surgical Oncology, 2011, 37, 737-746.	0.5	52
53	Growing tumor vessels: More than one way to skin a cat â€“ Implications for angiogenesis targeted cancer therapies. Molecular Aspects of Medicine, 2011, 32, 71-87.	2.7	92
54	Use of bevacizumab in elderly patients with metastatic colorectal cancer: Review. Journal of Geriatric Oncology, 2011, 2, 64-71.	0.5	6
55	Surgery of the primary in stage IV colorectal cancer with unresectable metastases. European Journal of Cancer, 2011, 47, S61-S66.	1.3	37
56	Bevacizumab in the management of colorectal cancer: A review. Journal of Solid Tumors, 2011, 1, .	0.1	1
57	Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. Chinese Journal of Cancer, 2011, 30, 682-689.	4.9	103
59	Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy. Pharmacogenetics and Genomics, 2011, 21, 18-25.	0.7	49
60	Conversion treatment of hepatic metastases of colon adenocarcinoma by bevacizumab and FOLFOX. Anti-Cancer Drugs, 2011, 22, S1-S7.	0.7	0

#	Article	IF	Citations
61	Clinical guidance on the perioperative use of targeted agents in solid tumor oncology. Asia-Pacific Journal of Clinical Oncology, 2011, 7, 106-113.	0.7	9
62	Safety of Presurgical Targeted Therapy in the Setting of Metastatic Renal Cell Carcinoma. European Urology, 2011, 60, 964-971.	0.9	89
63	Osteonecrosis of The Jaw: Dental Outcomes in Metastatic Breast Cancer Patients Treated With Bisphosphonates With/Without Bevacizumab. Clinical Breast Cancer, 2011, 11, 252-257.	1.1	33
64	Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1379-1396.	1.2	27
65	Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis. International Journal of Colorectal Disease, 2011, 26, 823-833.	1.0	63
66	The pooled analysis of efficacy and safety profiles of bevacizumab in Chinese cancer patients. Chinese-German Journal of Clinical Oncology, 2011, 10, 621-625.	0.1	1
67	Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review. Angiogenesis, 2011, 14, 135-141.	3.7	62
68	External Validation of Two Nomograms for Predicting Patient Survival After Hepatic Resection for Metastatic Colorectal Cancer. World Journal of Surgery, 2011, 35, 2275-2282.	0.8	14
69	Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. Cancer Chemotherapy and Pharmacology, 2011, 68, 1207-1213.	1.1	67
70	Recent developments and future perspectives in the systemic treatment of metastatic colorectal cancer. Memo - Magazine of European Medical Oncology, 2011, 4, 75-78.	0.3	1
71	Targeted agents: review of toxicity in the elderly metastatic colorectal cancer patients. Targeted Oncology, 2011, 6, 245-251.	1.7	6
72	The Role of Peri-operative Chemotherapy for Resectable Colorectal Liver Metastasis: What Does the Evidence Support?. Journal of Gastrointestinal Surgery, 2011, 15, 410-415.	0.9	11
73	Liver Resection for Colorectal Metastases: Is There an Age Limit? The Japanese Perspective. Current Colorectal Cancer Reports, 2011, 7, 187-190.	1.0	0
74	Is There a Future for Bevacizumab in the Adjuvant Setting After the C-08 and AVANT Trials?. Current Colorectal Cancer Reports, 2011, 7, 246-251.	1.0	0
75	Treatment of colorectal liver metastases. World Journal of Surgical Oncology, 2011, 9, 154.	0.8	69
76	Late Anastomotic Dehiscence during Bevacizumab Therapy for Patients with Colorectal Cancer. Clinical Oncology, 2011, 23, 497-498.	0.6	10
77	XELOX in colorectal cancer: a convenient option for the future?. Expert Review of Gastroenterology and Hepatology, 2011, 5, 9-19.	1.4	7
78	Antiangiogenic therapies: is VEGF-A inhibition alone enough?. Expert Review of Anticancer Therapy, 2011, 11, 485-496.	1.1	4

#	Article	IF	Citations
79	Retrospective Cohort Study on the Safety and Efficacy of Bevacizumab with Chemotherapy for Metastatic Colorectal Cancer Patients: The HGCSG0801 Study. Japanese Journal of Clinical Oncology, 2011, 41, 490-497.	0.6	9
80	Making sense of anti-EGFR plus oxaliplatin-based therapy in the first-line treatment of metastatic colorectal cancer. Future Oncology, 2011, 7, 223-226.	1.1	0
81	Optimizing the Efficacy of First-Line Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer. BioDrugs, 2011, 25, 43-50.	2.2	4
82	First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients. Annals of Oncology, 2011, 22, 595-602.	0.6	92
83	Curing patients with liver metastases from colorectal cancer. Drug and Therapeutics Bulletin, 2011, 49, 42-45.	0.3	2
84	Pneumothorax After Bevacizumab-containing Chemotherapy: A Case Report. Japanese Journal of Clinical Oncology, 2011, 41, 269-271.	0.6	32
85	Regarding â€˜Treatment of Colorectal Cancer with and without Bevacizumab: A Phase III Studyâ€™. Oncology, 2011, 80, 135-137.	0.9	2
86	Simultaneous surgery for primary colorectal cancer and metastatic lesions?. Scandinavian Journal of Gastroenterology, 2012, 47, 269-276.	0.6	9
87	First description of an uterine perforation potentially imputable to treatment with bevacizumab. Acta OncolÃ³gica, 2012, 51, 1102-1104.	0.8	1
88	Registries and Randomized Trials in Assessing the Effects of Bevacizumab in Colorectal Cancer: Is There a Common Theme?. Journal of Clinical Oncology, 2012, 30, 580-581.	0.8	15
89	Use of bevacizumab in the treatment of metastatic colorectal cancer. British Journal of Hospital Medicine (London, England: 2005), 2012, 73, 25-30.	0.2	1
90	Bevacizumab in endometrial cancer treatment. Expert Opinion on Biological Therapy, 2012, 12, 649-658.	1.4	15
91	Anti-VEGF Therapies in the Clinic. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a006577-a006577.	2.9	196
92	Antiangiogenesis therapy in the treatment of metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 2012, 4, 301-319.	1.4	26
93	Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer. Oncologist, 2012, 17, 513-524.	1.9	67
94	Safety Verification Trials of mFOLFIRI and Sequential IRIS + Bevacizumab as First- or Second-Line Therapies for Metastatic Colorectal Cancer in Japanese Patients. Oncology, 2012, 83, 101-107.	0.9	9
95	Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: Meta-analysis of randomized controlled trials. Oncology Letters, 2012, 3, 831-838.	0.8	19
96	Cardiotoxicity of Molecularly Targeted Agents. Current Cardiology Reviews, 2012, 7, 221-233.	0.6	36

#	Article	IF	Citations
97	Volumetric Analysis of Remnant Liver Regeneration After Major Hepatectomy in Bevacizumab-Treated Patients. Annals of Surgery, 2012, 256, 755-762.	2.1	29
98	Future of targeted agents in metastatic colorectal cancer. Colorectal Cancer, 2012, 1, 433-443.	0.8	12
99	Suppression of heat shock protein 27 expression promotes 5-fluorouracil sensitivity in colon cancer cells in a xenograft model. Oncology Reports, 2012, 28, 1269-1274.	1.2	25
100	Optimizing first-line chemotherapy for metastatic colorectal cancer. Colorectal Cancer, 2012, 1, 241-253.	0.8	0
101	Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer. Annals of Oncology, 2012, 23, 1503-1511.	0.6	21
102	Treatment Patterns and Clinical Outcomes in Patients With Metastatic Colorectal Cancer Initially Treated with FOLFOXâ€“Bevacizumab or FOLFIRIâ€“Bevacizumab: Results From ARIES, a Bevacizumab Observational Cohort Study. Oncologist, 2012, 17, 1486-1495.	1.9	91
103	First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study. Oncologist, 2012, 17, 15-25.	1.9	192
104	Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: a retrospective Italian study. Investigational New Drugs, 2012, 30, 1978-1983.	1.2	8
105	Fate of metastatic foci after chemotherapy and usefulness of contrastâ€enhanced intraoperative ultrasonography to detect minute hepatic lesions. Journal of Hepato-Biliary-Pancreatic Sciences, 2012, 19, 509-514.	1.4	6
106	Therapeutic strategies for hepatic metastasis of colorectal cancer: overview. Journal of Hepato-Biliary-Pancreatic Sciences, 2012, 19, 523-527.	1.4	27
107	Surgical Outcomes in Inflammatory Bowel Disease Patients and the Potential Impact of Biologic Therapies. Seminars in Colon and Rectal Surgery, 2012, 23, 89-93.	0.2	2
108	An observational study of bevacizumab combined with FOLFIRI as the first-line treatment in metastatic colorectal cancer. Genomic Medicine, Biomarkers, and Health Sciences, 2012, 4, 122-127.	0.3	1
109	Diaphragmatic rupture, a new complication of Bevacizumab. European Journal of Surgical Oncology, 2012, 38, 1079-1081.	0.5	4
110	Individual Fluorouracil Dose Adjustment in FOLFOX Based on Pharmacokinetic Follow-Up Compared With Conventional Body-Area-Surface Dosing: A Phase II, Proof-of-Concept Study. Clinical Colorectal Cancer, 2012, 11, 263-267.	1.0	68
111	Uso de bevacizumab en pacientes con cÃ¡ncer de colon metastÃ¡sico en el Instituto Nacional de CancerologÃa: una serie de casos. Revista Colombiana De CancerologÃa, 2012, 16, 227-233.	0.0	2
112	Patterns of treatment with chemotherapy and monoclonal antibodies for metastatic colorectal cancer in Western Europe. Current Medical Research and Opinion, 2012, 28, 221-229.	0.9	28
113	Bevacizumab plus chemotherapy in metastatic colorectal cancer patients treated in clinical practice. Future Oncology, 2012, 8, 1193-1197.	1.1	4
114	Bevacizumab every 4Âweeks is as effective as every 2Âweeks in combination with biweekly FOLFIRI in metastatic colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2012, 138, 1845-1852.	1.2	4

#	Article	IF	Citations
115	Effectiveness of Bevacizumab With First-Line Combination Chemotherapy for Medicare Patients With Stage IV Colorectal Cancer. Journal of Clinical Oncology, 2012, 30, 608-615.	0.8	117
116	Targeting Tumor-Associated Endothelial Cells: Anti-VEGFR2 Immunoliposomes Mediate Tumor Vessel Disruption and Inhibit Tumor Growth. Clinical Cancer Research, 2012, 18, 454-464.	3.2	91
117	An Update on the Current and Emerging Targeted Agents in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2012, 11, 1-13.	1.0	117
118	Effectiveness of Liver Metastasectomies in Patients With Metastatic Colorectal Cancer Treated With FIr-B/FOx Triplet Chemotherapy Plus Bevacizumab. Clinical Colorectal Cancer, 2012, 11, 119-126.	1.0	29
119	Safety of bevacizumab in metastatic breast cancer patients undergoing surgery. European Journal of Cancer, 2012, 48, 475-481.	1.3	23
120	Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: Results from a large treatment observational cohort study. European Journal of Cancer, 2012, 48, 1126-1132.	1.3	46
121	Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature. BMC Cancer, 2012, 12, 356.	1.1	23
122	Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer. Acta OncolÃ³gica, 2012, 51, 867-872.	0.8	20
123	Oncological Management of Unresectable Liver Metastases. Digestive Diseases, 2012, 30, 137-142.	0.8	11
124	Patient selection criteria for selective internal radiation therapy and integration into treatment guidelines. European Journal of Cancer, Supplement, 2012, 10, 76-80.	2.2	1
125	Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer. European Journal of Cancer, 2012, 48, 3140-3149.	1.3	19
126	Role of the METâ€“HGF axis in colorectal cancer: precepts and prospects. Colorectal Cancer, 2012, 1, 329-341.	0.8	6
127	Treatment of colorectal cancer in older patients. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 716-725.	8.2	43
128	Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study). Medical Oncology, 2012, 29, 2842-2848.	1.2	15
129	Drugs that act on the immune system: cytokines and monoclonal antibodies. Side Effects of Drugs Annual, 2012, 34, 579-607.	0.6	0
130	Metastatic colorectal cancer: Current treatment and future options for improved survivalMedical approach â€“ present status. Scandinavian Journal of Gastroenterology, 2012, 47, 296-314.	0.6	53
131	Meeting the biologic challenge of colorectal metastases. Clinical and Experimental Metastasis, 2012, 29, 821-839.	1.7	42
132	Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy. BMC Cancer, 2012, 12, 620.	1.1	16

#	Article	IF	Citations
133	Antiangiogenic Therapy of Colorectal Cancer: State of the Art, Challenges and New Approaches. International Journal of Biological Markers, 2012, 27, 286-294.	0.7	4
134	Chemotherapy and target therapy as neo-adjuvant approach for initially unresectable colorectal liver metastases. Oncology Reviews, 2012, 6, 6.	0.8	2
135	Novel anti-angiogenic agents for colorectal cancer. Are we moving on?. Journal of Solid Tumors, 2012, 3, .	0.1	0
136	Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer. OncoTargets and Therapy, 2012, 5, 199.	1.0	5
137	Systemic chemotherapy for hepatic colorectal cancer. , 2012, , 1434-1443.e3.		0
138	Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer. Investigational New Drugs, 2012, 30, 1690-1696.	1.2	22
139	Incidence and Management of Gastrointestinal Perforation from Bevacizumab in Advanced Cancers. Current Oncology Reports, 2012, 14, 277-284.	1.8	44
140	A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2012, 69, 1339-1344.	1.1	9
142	Clinical and Cost Effectiveness of Bevacizumab + FOLFIRI Combination Versus FOLFIRI Alone as First-Line Treatment of Metastatic Colorectal Cancer in South Korea. Clinical Therapeutics, 2012, 34, 1408-1419.	1.1	14
143	The Role of Biological Agents in the Resection of Colorectal Liver Metastases. Clinical Oncology, 2012, 24, 432-442.	0.6	11
144	Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors. Critical Reviews in Oncology/Hematology, 2012, 81, 136-150.	2.0	14
145	A Systematic Review of Clinical Response and Survival Outcomes of Downsizing Systemic Chemotherapy and Rescue Liver Surgery in Patients with Initially Unresectable Colorectal Liver Metastases. Annals of Surgical Oncology, 2012, 19, 1292-1301.	0.7	153
146	Stage IV Colorectal Cancers: An Analysis of Factors Predicting Outcome and Survival in 728 cases. Journal of Gastrointestinal Surgery, 2012, 16, 603-612.	0.9	26
147	5-Fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity. Cancer Chemotherapy and Pharmacology, 2012, 69, 57-64.	1.1	72
148	Are high initial CEA and CA 19â€“9 levels associated with the presence of K-ras mutation in patients with metastatic colorectal cancer?. Tumor Biology, 2013, 34, 2233-2239.	0.8	25
149	Infusion of Bevacizumab increases the risk of intestinal perforation: results on a series of 143 patients consecutively treated. Updates in Surgery, 2013, 65, 121-124.	0.9	13
150	A case report of rectal perforation associated with bevacizumab treatment after carbon ion radiotherapy for recurrent rectal cancer. International Cancer Conference Journal, 2013, 2, 220-223.	0.2	1
151	A case of successful cure of rectal adenocarcinoma and synchronous multiple hepatic metastases with massive biliary tumor thrombi by two-stage surgery and systemic therapy. International Cancer Conference Journal, 2013, 2, 139-144.	0.2	1

#	Article	IF	Citations
152	Regorafenib: from bench to bedside in colorectal cancer. Expert Review of Clinical Pharmacology, 2013, 6, 243-248.	1.3	4
154	A Systematic Review of Repeat Hepatectomy for Recurrent Colorectal Liver Metastases. Journal of Gastrointestinal Surgery, 2013, 17, 1312-1321.	0.9	52
155	Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma. Clinical and Translational Oncology, 2013, 15, 460-466.	1.2	6
156	Treatment Strategy for Elderly Patients with Metastatic Colorectal Cancer: A Review of the Systemic Chemotherapy Options. Current Colorectal Cancer Reports, 2013, 9, 213-222.	1.0	1
157	Reasons for avoidance of bevacizumab with first-line FOLFOX for advanced colorectal cancer. International Journal of Clinical Oncology, 2013, 18, 435-438.	1.0	1
158	Bevacizumab-induced perforation of the gastrointestinal tract: clinical and radiographic findings in 11 patients. Abdominal Imaging, 2013, 38, 265-272.	2.0	20
159	Overview of biomarkers in metastatic colorectal cancer: Tumour, blood and patient-related factors. Critical Reviews in Oncology/Hematology, 2013, 85, 121-135.	2.0	19
160	Surgical Resection after Downsizing Chemotherapy for Initially Unresectable Locally Advanced Biliary Tract Cancer: A Retrospective Single-center Study. Annals of Surgical Oncology, 2013, 20, 318-324.	0.7	133
161	Bevacizumab in Stage II-III Colon Cancer: 5-Year Update of the National Surgical Adjuvant Breast and Bowel Project C-08 Trial. Journal of Clinical Oncology, 2013, 31, 359-364.	0.8	187
162	Adverse Events Associated With Bevacizumab and Chemotherapy in Older Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2013, 12, 204-213.e1.	1.0	15
163	A Phase 1B Study of Dulanermin in Combination With Modified FOLFOX6 Plus Bevacizumab in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2013, 12, 248-254.	1.0	48
165	Trends in the Multimodality Treatment of Resectable Colorectal Liver Metastases: an Underutilized Strategy. Journal of Gastrointestinal Surgery, 2013, 17, 1938-1946.	0.9	11
166	Safety of Bevacizumab in Treating Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis of All Randomized Clinical Trials. Clinical Drug Investigation, 2013, 33, 779-788.	1.1	30
167	Chemotherapy with bevacizumab for metastatic colorectal cancer: a retrospective review of 181 Japanese patients. International Journal of Clinical Oncology, 2013, 18, 689-695.	1.0	5
168	Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels. BMC Cancer, 2013, 13, 611.	1.1	18
169	A retrospective analysis of periodontitis during bevacizumab treatment in metastatic colorectal cancer patients. International Journal of Clinical Oncology, 2013, 18, 1020-1024.	1.0	6
170	Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy. Investigational New Drugs, 2013, 31, 183-191.	1.2	11
171	Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncology, The, 2013, 14, 29-37.	5.1	997

#	Article	IF	Citations
172	XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study. Cancer Chemotherapy and Pharmacology, 2013, 71, 257-264.	1.1	21
173	Cost-Effectiveness of Gene-Expression Profiling for Tumor-Site Origin. Value in Health, 2013, 16, 46-56.	0.1	6
174	FOLFIRI-Bevacizumab As First-Line Chemotherapy in 3500 Patients With Advanced Colorectal Cancer: A Pooled Analysis of 29 Published Trials. Clinical Colorectal Cancer, 2013, 12, 145-151.	1.0	59
175	Adverse Events Associated With Antiangiogenic Agents in Combination With Cytotoxic Chemotherapy in Metastatic Colorectal Cancer and Their Management. Clinical Colorectal Cancer, 2013, 12, 86-94.	1.0	12
176	Bevacizumab Treatment Before Resection of Colorectal Liver Metastases: Safety, Recovery of Liver Function, Pathologic Assesment. Pathology and Oncology Research, 2013, 19, 501-508.	0.9	9
177	Management of advanced colorectal cancer, part 2. American Journal of Health-System Pharmacy, 2013, 70, 491-506.	0.5	17
178	Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial. British Journal of Cancer, 2013, 108, 1566-1570.	2.9	36
179	Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: Current evidence and future perspectives. Cancer Treatment Reviews, 2013, 39, 908-924.	3.4	37
180	Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients. Medical Oncology, 2013, 30, 327.	1.2	40
181	Role of targeted agents in metastatic colorectal cancer. Targeted Oncology, 2013, 8, 83-96.	1.7	58
182	Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study. Investigational New Drugs, 2013, 31, 1035-1043.	1.2	12
183	A systematic review of twoâ€stage hepatectomy in patients with initially unresectable colorectal liver metastases. Hpb, 2013, 15, 483-491.	0.1	174
184	Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis. World Journal of Surgical Oncology, 2013, 11, 306.	0.8	59
185	The Tower of Babel of liver metastases from colorectal cancer: Are we ready for one language?. Critical Reviews in Oncology/Hematology, 2013, 85, 332-341.	2.0	8
186	Hepatic resection combined with radiofrequency ablation for initially unresectable colorectal liver metastases after effective chemotherapy is a safe procedure with a low incidence of local recurrence. International Journal of Clinical Oncology, 2013, 18, 847-855.	1.0	39
187	An Open-Label Safety Study of First-Line Bevacizumab in Combination with Standard Chemotherapy in Chinese Patients with Metastatic Colorectal Cancer Treated in an Expanded Access Program in Taiwan. Oncology, 2013, 84, 299-304.	0.9	3
188	Bevacizumab-Based Therapy for Colorectal Cancer: Experience from a Large Canadian Cohort at the Jewish General Hospital between 2004 and 2009. Current Oncology, 2013, 20, 247-251.	0.9	6
189	Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. Annals of Oncology, 2013, 24, 1560-1567.	0.6	79

#	Article	IF	Citations
190	Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer. OncoTargets and Therapy, 2013, 6, 53.	1.0	13
191	A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial. Annals of Oncology, 2013, 24, 2335-2341.	0.6	68
192	Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. Annals of Oncology, 2013, 24, 1580-1587.	0.6	61
193	Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials. Oncologist, 2013, 18, 1004-1012.	1.9	210
194	A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer. Clinical Cancer Research, 2013, 19, 258-267.	3.2	165
195	Effectiveness and Safety of Intensive Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, in Young-Elderly Metastatic Colorectal Cancer Patients. BioMed Research International, 2013, 2013, 1-9.	0.9	15
196	Secondâ€line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wildâ€type <scp>KRAS</scp>. Cancer Science, 2013, 104, 473-480.	1.7	6
197	Developing a national database for metastatic colorectal cancer management: perspectives and challenges. Internal Medicine Journal, 2013, 43, 1224-1231.	0.5	33
198	Bevacizumab + Capecitabine as Maintenance Therapy after Initial Bevacizumab + XELOX Treatment in Previously Untreated Patients with Metastatic Colorectal Cancer: Phase III â€˜Stop and Go' Study Results - A Turkish Oncology Group Trial. Oncology, 2013, 85, 328-335.	0.9	59
199	Molecularly targeted therapy: toxicity and quality of life considerations in advanced colorectal cancer. Expert Review of Anticancer Therapy, 2013, 13, 1181-1191.	1.1	10
200	The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2013, 13, 427-438.	1.1	13
201	Markers of Sensitivity and Resistance to EGFR Inhibitors in Colorectal Cancer. , 2013, , 183-232.		0
202	Conversion chemotherapy followed by hepatic resection in colorectal cancer with initially unresectable liver-limited metastases. Oncology Reports, 2013, 30, 2992-2998.	1.2	11
203	Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma. Oncology Letters, 2013, 5, 637-640.	0.8	10
204	Cost-Effectiveness of First-Line Treatments for Patients with Kras Wild-Type Metastatic Colorectal Cancer. Current Oncology, 2014, 21, 541-550.	0.9	21
205	A single-institution experience with bevacizumab in the treatment of metastatic colorectal cancer and in conjunction with liver resection. OncoTargets and Therapy, 2014, 7, 1177.	1.0	2
206	Advances and new perspectives in the treatment of metastatic colon cancer. World Journal of Gastrointestinal Oncology, 2014, 6, 211.	0.8	25
207	Management of locally advanced and metastatic colon cancer in elderly patients. World Journal of Gastroenterology, 2014, 20, 1910.	1.4	17

#	Article	IF	Citations
208	Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?. World Journal of Gastroenterology, 2014, 20, 6092.	1.4	27
209	Sequencing of treatment in metastatic colorectal cancer: Where to fit the target. World Journal of Gastroenterology, 2014, 20, 1993.	1.4	23
210	Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study. BMC Cancer, 2014, 14, 737.	1.1	4
211	Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study. BMC Cancer, 2014, 14, 897.	1.1	54
212	Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90Ì± in human colorectal cancer. British Journal of Cancer, 2014, 111, 497-505.	2.9	41
213	Survival and Lifetime Costs Associated With First-Line Bevacizumab Use in Older Patients With Metastatic Colorectal Cancer. Oncologist, 2014, 19, 892-899.	1.9	19
214	Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study results. BMC Cancer, 2014, 14, 761.	1.1	15
215	Retrospective analysis on the efficacy of bevacizumab with FOLFOX as a first-line treatment in Japanese patients with metastatic colorectal cancer. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 322-329.	0.7	10
216	Incidence and Relevance of Proteinuria in Bevacizumab-Treated Patients: Pooled Analysis from Randomized Controlled Trials. American Journal of Nephrology, 2014, 40, 75-83.	1.4	41
217	Personalized treatment is better than one treatment fits all in the management of patients with mCRC: a consensus statement. Future Oncology, 2014, 10, 2643-2657.	1.1	6
218	Bevacizumab Efficacy in Metastatic Colorectal Cancer is Dependent on Primary Tumor Resection. Annals of Surgical Oncology, 2014, 21, 1632-1640.	0.7	23
219	Strategies in the Multidisciplinary Management of Synchronous Colorectal Cancer and Resectable Liver Metastases. Current Colorectal Cancer Reports, 2014, 10, 227-238.	1.0	1
220	A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer. Investigational New Drugs, 2014, 32, 561-568.	1.2	2
221	Postoperative complications following neoadjuvant bevacizumab treatment for advanced colorectal cancer. Surgery Today, 2014, 44, 1300-1306.	0.7	24
223	Panitumumab Monotherapy as a Second-line Treatment in Metastasised Colorectal Cancer: A Single Centre Experience. Clinical Oncology, 2014, 26, 135-141.	0.6	3
224	Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort. Targeted Oncology, 2014, 9, 311-319.	1.7	21
225	Methods of overcoming treatment resistance in colorectal cancer. Critical Reviews in Oncology/Hematology, 2014, 89, 217-230.	2.0	58
226	Occurrence and survival of synchronous pulmonary metastases in colorectal cancer: A nationwide cohort study. European Journal of Cancer, 2014, 50, 447-456.	1.3	38

#	Article	IF	Citations
227	Bevacizumab: A Review of Its Use in Advanced Cancer. Drugs, 2014, 74, 1891-1925.	4.9	142
228	Indication for neoadjuvant chemotherapy in patients with colorectal liver metastases based on a nomogram that predicts disease-free survival. Journal of Hepato-Biliary-Pancreatic Sciences, 2014, 21, 881-888.	1.4	17
229	Comparative cost-effectiveness of bevacizumab-irinotecan-fluorouracil versus irinotecan-fluorouracil in first-line metastatic colorectal cancer. Journal of Oncology Pharmacy Practice, 2014, 20, 341-350.	0.5	4
230	Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics. Oncologie, 2014, 16, 267-276.	0.2	2
231	Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer. Investigational New Drugs, 2014, 32, 729-738.	1.2	27
232	Systemic Chemotherapy for Resectable Hepatic Colorectal Metastases: Adjuvant, Neoadjuvant, or Not at All?. Current Surgery Reports, 2014, 2, 1.	0.4	1
233	Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry. BMC Gastroenterology, 2014, 14, 53.	0.8	15
234	Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70Âyears) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG). BMC Cancer, 2014, 14, 277.	1.1	12
235	Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis. BMC Cancer, 2014, 14, 323.	1.1	16
236	FOLFIRIÂ® and Bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms. BMC Research Notes, 2014, 7, 260.	0.6	15
237	Refining the Chemotherapy Approach for Older Patients With Colon Cancer. Journal of Clinical Oncology, 2014, 32, 2570-2580.	0.8	54
238	Sequencing of Antiangiogenic Agents in the Treatment of Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2014, 13, 135-144.	1.0	27
239	Current management of colorectal liver metastases. Colorectal Cancer, 2014, 3, 163-181.	0.8	1
240	Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen. International Journal of Oncology, 2014, 44, 1820-1830.	1.4	10
241	Role of surgery in colorectal cancer liver metastases. World Journal of Gastroenterology, 2014, 20, 6113.	1.4	176
242	Primary tumor resection in colorectal cancer with unresectable synchronous metastases: A review. World Journal of Gastrointestinal Oncology, 2014, 6, 156.	0.8	48
244	SIR-Spheres^{Â®} radioembolization in the management of metastatic colorectal cancer: a medical oncology perspective. Colorectal Cancer, 2014, 3, 331-343.	0.8	0
245	Inhibitory effect of maple syrup on the cell growth and invasion of human colorectal cancer cells. Oncology Reports, 2015, 33, 1579-1584.	1.2	12

#	Article	IF	Citations
246	Randomized phase <scp>II</scp>/<scp>III</scp> clinical trial of elpamotide for patients with advanced pancreatic cancer: <scp>PEGASUS</scp>â€<scp>PC</scp> Study. Cancer Science, 2015, 106, 883-890.	1.7	78
247	Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on Kâ€ras status for unresectable colorectal liver metastasis (BECK study). Journal of Hepato-Biliary-Pancreatic Sciences, 2015, 22, 634-645.	1.4	21
248	MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer. Cell Proliferation, 2015, 48, 503-510.	2.4	58
249	Bevacizumab treatment in the elderly patient with metastatic colorectal cancer. Clinical Interventions in Aging, 2015, 10, 127.	1.3	2
250	Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer. OncoTargets and Therapy, 2015, 8, 529.	1.0	7
251	Uracil/tegafur as a possible salvage therapy in chemo-refractory colorectal cancer patients: a single institutional retrospective study. Wspolczesna Onkologia, 2015, 5, 385-390.	0.7	2
252	Bevacizumab nel trattamento del carcinoma metastatico del colon-retto: l'RFOM nell'esperienza dell'A.O. Universitaria Senese. Global & Regional Health Technology Assessment, 2015, 2, GRHTA.5000188.	0.2	0
253	Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy. Frontiers in Oncology, 2015, 5, 152.	1.3	26
254	Bleeding after Bevacizumab Treatment in Patients with Metastatic Colorectal Cancer. Tumori, 2015, 101, 46-51.	0.6	8
255	Angiogenesis inhibitors rechallenge in patients with advanced non-small-cell lung cancer: a pooled analysis of randomized controlled trials. OncoTargets and Therapy, 2015, 8, 2775.	1.0	8
256	Anticoagulant therapy for venous thromboembolism detected by Doppler ultrasound in patients with metastatic colorectal cancer receiving bevacizumab. OncoTargets and Therapy, 2015, 8, 243.	1.0	1
257	Enhancing T Cell Performance Against Cancer in Combination Treatment Strategies. Cancer Drug Discovery and Development, 2015, , 245-258.	0.2	0
258	Comparison of minimally invasive and open colorectal resections for patients undergoing simultaneous R0 resection for liver metastases: a propensity score analysis. International Journal of Colorectal Disease, 2015, 30, 385-395.	1.0	44
259	First-line chemotherapy for mCRCâ€"a review and evidence-based algorithm. Nature Reviews Clinical Oncology, 2015, 12, 607-619.	12.5	138
260	A Phase I Study of UGT1A1 *28/*6 Genotype-Directed Dosing of Irinotecan (CPT-11) in Korean Patients with Metastatic Colorectal Cancer Receiving FOLFIRI. Oncology, 2015, 88, 164-172.	0.9	19
261	The Place of Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer. Cancers, 2015, 7, 439-449.	1.7	2
262	Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castrationâ€resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer, 2015, 121, 1025-1031.	2.0	32
263	Endostar in combination with modified FOLFOX6 as an initial therapy in advanced colorectal cancer patients: a phase I clinical trial. Cancer Chemotherapy and Pharmacology, 2015, 75, 547-557.	1.1	16

#	Article	IF	Citations
264	Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2015, 75, 993-1004.	1.1	12
265	Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents. Targeted Oncology, 2015, 10, 453-465.	1.7	18
266	The Association of Serum Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Thymidine Kinase, and Tissue Polypeptide Specific Antigen with Outcomes of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab: a Retrospective Study. Targeted Oncology, 2015, 10, 549-555.	1.7	5
267	Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view. BMC Gastroenterology, 2015, 15, 37.	0.8	17
268	GRECCAR 8: impact on survival of the primary tumor resection in rectal cancer with unresectable synchronous metastasis: a randomized multicentre study. BMC Cancer, 2015, 15, 47.	1.1	29
269	Linking the future of anticancer metal-complexes to the therapy of tumour metastases. Chemical Society Reviews, 2015, 44, 8818-8835.	18.7	190
270	Efficacy of Oxaliplatin-based Chemotherapy+Bevacizumab as First-line Treatment for Advanced Colorectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 227-233.	0.6	26
271	Observational study of adjuvant therapy with capecitabine in colon cancer. Current Medical Research and Opinion, 2015, 31, 731-741.	0.9	3
272	Fluorouracil, leucovorin and irinotecan associated with aflibercept can induce microscopic colitis in metastatic colorectal cancer patients. Investigational New Drugs, 2015, 33, 1263-1266.	1.2	5
273	Clinical outcomes of Chinese patients with metastatic colorectal cancer receiving first-line bevacizumab-containing treatment. Medical Oncology, 2015, 32, 469.	1.2	9
274	An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer. Expert Opinion on Investigational Drugs, 2015, 24, 1307-1320.	1.9	7
275	Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting. British Journal of Cancer, 2015, 113, 1027-1034.	2.9	34
276	Bevacizumab beyond first disease progression in metastatic colorectal cancer: a review of recent clinical trial data. Colorectal Cancer, 2015, 4, 13-25.	0.8	0
277	Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2015, 15, 1267-1281.	1.1	17
278	Regorafenib suppresses sinusoidal obstruction syndrome in rats. Journal of Surgical Research, 2015, 193, 693-703.	0.8	22
279	Immune Effects of Bevacizumab: Killing Two Birds with One Stone. Cancer Microenvironment, 2015, 8, 15-21.	3.1	49
280	An observational cohort study of bevacizumab and chemotherapy in metastatic colorectal cancer patients: safety and efficacy with analysis by age group. Targeted Oncology, 2015, 10, 55-63.	1.7	17
281	The â€˜real-lifeâ€™ impact of adding bevacizumab to first-line therapy in metastatic colorectal cancer patients: A large Israeli retrospective cohort study. Acta OncolÃ³gica, 2015, 54, 164-170.	0.8	12

#	Article	IF	Citations
282	Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: Results from a large German community-based observational cohort study. Acta OncolÃ³gica, 2015, 54, 171-178.	0.8	14
284	Early detection of poor outcome in patients with metastatic colorectal cancer: tumor kinetics evaluated by circulating tumor cells. OncoTargets and Therapy, 2016, Volume 9, 7503-7513.	1.0	31
285	A Novel Computational Tool for Mining Real-Life Data: Application in the Metastatic Colorectal Cancer Care Setting. PLoS ONE, 2016, 11, e0154689.	1.1	0
286	A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity. Journal of Cardiovascular Medicine, 2016, 17, e93-e104.	0.6	37
287	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology, 2016, 27, 1386-1422.	0.6	2,545
288	A Rupture of a Lung Metastatic Lesion of Colon Cancer, Leading to Pneumothorax Caused by Bevacizumab. Internal Medicine, 2016, 55, 3125-3129.	0.3	10
289	Changes in plasma hormones and heart rate variability in patients receiving the cardiotoxic anti-cancer agent bevacizumab. International Journal of Cardiology, 2016, 219, 25-26.	0.8	1
290	Primary Tumor Resection and Multimodality Treatment for Patients with Metastatic Colon Cancer. Annals of Surgical Oncology, 2016, 23, 1815-1823.	0.7	13
291	Decision-making in geriatric oncology: systemic treatment considerations for older adults with colon cancer. Expert Review of Gastroenterology and Hepatology, 2016, 10, 1321-1340.	1.4	17
292	Pulmonary metastasectomy in elderly colorectal cancer patients: a retrospective single center study. Updates in Surgery, 2016, 68, 357-367.	0.9	10
293	Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer. Medicine (United States), 2016, 95, e4531.	0.4	14
294	Bevacizumab with preoperative chemotherapy versus preoperative chemotherapy alone for colorectal cancer liver metastases. Medicine (United States), 2016, 95, e4767.	0.4	7
295	Cancer therapy-related complications in the bowel and mesentery: an imaging perspective. Abdominal Radiology, 2016, 41, 2031-2047.	1.0	12
296	Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer - results from a non-interventional observation study. BMC Cancer, 2016, 16, 82.	1.1	12
297	Managing the Primary Tumor with Unresectable Synchronous Colorectal Metastases. Current Colorectal Cancer Reports, 2016, 12, 170-179.	1.0	0
298	Safety of vemurafenib in patients with BRAF V600 mutated metastatic melanoma: the Spanish experience. Clinical and Translational Oncology, 2016, 18, 1147-1157.	1.2	17
299	Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer. Surgical Oncology, 2016, 25, 190-199.	0.8	12
300	Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice. BMC Cancer, 2016, 16, 110.	1.1	7

#	Article	IF	Citations
301	Bevacizumab safety in Japanese patients with colorectal cancer. Japanese Journal of Clinical Oncology, 2016, 46, 234-240.	0.6	31
302	The optimal regimen of bevacizumab for recurrent glioblastoma: does dose matter?. Journal of Neuro-Oncology, 2016, 127, 493-502.	1.4	21
303	G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab. Tumor Biology, 2016, 37, 6823-6830.	0.8	38
304	Effects of Cancer Stage and Treatment Differences on Racial Disparities in Survival From Colon Cancer: A United States Population-Based Study. Gastroenterology, 2016, 150, 1135-1146.	0.6	92
305	Optimizing Colorectal Cancer Care in Older Patients. Current Colorectal Cancer Reports, 2016, 12, 9-17.	1.0	0
306	Autophagy, a double-edged sword in anti-angiogenesis therapy. Medical Oncology, 2016, 33, 10.	1.2	56
307	Patterns of Care for Colorectal Liver Metastasis Within an Integrated Health System: Secular Trends and Outcomes. Annals of Surgical Oncology, 2017, 24, 23-30.	0.7	4
308	Baseline and On-Treatment Markers Determining Prognosis of First-Line Chemotherapy in Combination with Bevacizumab in Patients with Metastatic Colorectal Cancer. Oncology Research and Treatment, 2017, 40, 21-26.	0.8	5
309	Preoperative bevacizumab and surgery for colorectal liver metastases: a propensity score analysis. Langenbeck's Archives of Surgery, 2017, 402, 57-67.	0.8	4
310	Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas. , 2017, 174, 145-172.		22
311	Targeted Therapies in Elderly Patients with Metastatic Colorectal Cancer: A Review of the Evidence. Drugs and Aging, 2017, 34, 173-189.	1.3	5
312	Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors. Investigational New Drugs, 2017, 35, 782-790.	1.2	22
313	Randomized Phase III Study to Assess Efficacy and Safety of Adjuvant CAPOX with or without Bevacizumab in Patients after Resection of Colorectal Liver Metastases: HEPATICA study. Neoplasia, 2017, 19, 93-99.	2.3	29
314	Gastrointestinal Perforation and Fistula Formation in 5 Patients With Colorectal Cancer During Treatment With Regorafenib. Clinical Colorectal Cancer, 2017, 16, e109-e113.	1.0	7
315	KRAS mutation and primary tumor location do not affect efficacy of bevacizumab-containing chemotherapy in stagae IV colorectal cancer patients. Scientific Reports, 2017, 7, 14368.	1.6	13
316	The association of miR-126-3p, miR-126-5p and miR-664-3p expression profiles with outcomes of patients with metastatic colorectal cancer treated with bevacizumab. Tumor Biology, 2017, 39, 101042831770928.	0.8	24
317	Exposureâ€“response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. Cancer Chemotherapy and Pharmacology, 2017, 80, 599-608.	1.1	18
318	Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM). ESMO Open, 2017, 2, e000147.	2.0	36

#	Article	IF	Citations
319	Effectiveness of bevacizumab and cetuximab in metastatic colorectal cancer across selected public hospitals in Queensland. Asia-Pacific Journal of Clinical Oncology, 2017, 13, e253-e261.	0.7	4
320	Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT). Clinical Colorectal Cancer, 2017, 16, 129-140.e4.	1.0	12
321	Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies. Therapeutic Advances in Medical Oncology, 2017, 9, 106-126.	1.4	36
322	The impact of bevacizumab in metastatic colorectal cancer with an intact primary tumor: Results from a large prospective cohort study. Asia-Pacific Journal of Clinical Oncology, 2017, 13, 314-321.	0.7	7
323	Management of surgical challenges in actively treated cancer patients. Current Problems in Surgery, 2017, 54, 612-654.	0.6	10
324	Synovial metastasis of the knee in aKRASmutant rectal adenocarcinoma patient. BMJ Case Reports, 2017, 2017, bcr-2017-220008.	0.2	5
325	Long noncoding RNA CRNDE functions as a competing endogenous RNA to promote metastasis and oxaliplatin resistance by sponging miR-136 in colorectal cancer. OncoTargets and Therapy, 2017, Volume 10, 205-216.	1.0	74
326	Comparative Effectiveness of Up To Three Lines of Chemotherapy Treatment Plans for Metastatic Colorectal Cancer. MDM Policy and Practice, 2017, 2, 238146831772965.	0.5	3
327	Molecular targeted treatment of metastatic colorectal cancer: the cardiovascular adverse effects of Bevacizumab and Cetuximab. Medicine and Pharmacy Reports, 2017, 90, 377-384.	0.2	3
328	Promoter Methylation of RASSF1A indicates Prognosis for Patients with Stage II and III Colorectal Cancer Treated with Oxaliplatin-Based Chemotherapy. Medical Science Monitor, 2017, 23, 5389-5395.	0.5	21
329	Multidisciplinary approach of colorectal cancer liver metastases. World Journal of Clinical Oncology, 2017, 8, 190.	0.9	37
330	A Population-Based Study of Complications After Colorectal Surgery in Patients Who Have Received Bevacizumab. Diseases of the Colon and Rectum, 2018, 61, 306-313.	0.7	12
331	Potential lymphangiogenesis therapies: Learning from current antiangiogenesis therapiesâ€"A review. Medicinal Research Reviews, 2018, 38, 1769-1798.	5.0	51
332	Neither creatinine- nor cystatin C-estimated glomerular filtration rate is optimal in oncology patients treated with targeted agents. Nephrology Dialysis Transplantation, 2018, 33, 402-408.	0.4	9
333	Anticancer activity of new imidazole derivative of 1R,2R-diaminocyclohexane palladium and platinum complexes as DNA fluorescent probes. Journal of Biomolecular Structure and Dynamics, 2018, 36, 3058-3076.	2.0	29
334	Gastrointestinal perforation related to lenvatinib, an anti-angiogenic inhibitor that targets multiple receptor tyrosine kinases, in a patient with metastatic thyroid cancer. Investigational New Drugs, 2018, 36, 350-353.	1.2	12
335	Late anastomotic breakdown with bevacizumab in colorectal cancers, a case-based review. Irish Journal of Medical Science, 2018, 187, 333-336.	0.8	7
336	The hepatic microenvironment essentially determines tumor cell dormancy and metastatic outgrowth of pancreatic ductal adenocarcinoma. OncoImmunology, 2018, 7, e1368603.	2.1	33

#	Article	IF	Citations
337	Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, openâ€label, singleâ€arm, noncomparative trial. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 61-68.	0.7	8
338	Integrating geriatric assessment in the first line chemotherapy treatment in older patients with metastatic colorectal cancer: Results of a prospective observational cohort study (AVAPLUS). Journal of Geriatric Oncology, 2018, 9, 93-101.	0.5	14
339	Cancer-Associated Thrombosis: Beyond Clinical Practice Guidelinesâ€"A Multidisciplinary (SEMIâ€"SEOMâ€"SETH) Expert Consensus. TH Open, 2018, 02, e373-e386.	0.7	17
340	Iatrogenic pseudoaneurysm after bevacizumab therapy in patients with metastatic colorectal cancer: Two case reports. Molecular and Clinical Oncology, 2018, 9, 499-503.	0.4	7
341	Research progress on common adverse events caused by targeted therapy for colorectal cancer (Review). Oncology Letters, 2018, 16, 27-33.	0.8	25
342	Risk Factors and Adequate Management for Complications of Bevacizumab Treatment Requiring Surgical Intervention in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, e639-e645.	1.0	19
343	â€œVessels in the Stormâ€: Searching for Prognostic and Predictive Angiogenic Factors in Colorectal Cancer. International Journal of Molecular Sciences, 2018, 19, 299.	1.8	29
344	Seleno-short-chain chitosan induces apoptosis in human breast cancer cells through mitochondrial apoptosis pathway in vitro. Cell Cycle, 2018, 17, 1579-1590.	1.3	8
345	Toxicity of Cancer Therapies in Older Patients. Current Oncology Reports, 2018, 20, 64.	1.8	21
346	ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK. Clinical Colorectal Cancer, 2019, 18, 280-291.e5.	1.0	16
347	Beppu's Nomogram Score Is an Independent Prognostic Factor for Colorectal Liver Metastasis Receiving Perioperative Chemotherapy and/or Targeted Therapy. In Vivo, 2019, 33, 1301-1306.	0.6	7
348	Development and Validation of HPLC and HPTLC Methods for Therapeutic Drug Monitoring of Capecitabine in Colorectal Cancer Patients. Journal of Chromatographic Science, 2019, 57, 892-900.	0.7	2
349	Outcomes of Patients with Early Onset Colorectal Cancer Treated in a UK Specialist Cancer Center. Cancers, 2019, 11, 1558.	1.7	25
350	NIRâ€Ⅱ Fluorescence Endoscopy for Targeted Imaging of Colorectal Cancer. Advanced Healthcare Materials, 2019, 8, e1900974.	3.9	63
351	Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens. BMC Pharmacology & Toxicology, 2019, 20, 6.	1.0	4
352	The Hepatic Microenvironment and TRAIL-R2 Impact Outgrowth of Liver Metastases in Pancreatic Cancer after Surgical Resection. Cancers, 2019, 11, 745.	1.7	12
353	Rare case of a giant duodenal ulcer penetrating the pancreas during antiangiogenic treatment. BMJ Case Reports, 2019, 12, e228612.	0.2	3
354	Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice . OncoTargets and Therapy, 2019, Volume 12, 2159-2170.	1.0	8

#	Article	IF	Citations
355	Primary Tumor Resection in Patients with Incurable Localized or Metastatic Colorectal Cancer: A Systematic Review and Metaâ€analysis. World Journal of Surgery, 2019, 43, 1829-1840.	0.8	33
356	Survival Outcomes After Surgical Management of the Primary Tumor With and Without Radiotherapy for Metastatic Rectal Adenocarcinoma: A National Cancer Database (NCDB) Analysis. Clinical Colorectal Cancer, 2019, 18, e237-e243.	1.0	5
357	Efficacy and safety of bevacizumab-based maintenance therapy in metastatic colorectal cancer. Medicine (United States), 2019, 98, e18227.	0.4	11
358	Incidental Use of Beta-Blockers Is Associated with Outcome of Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Based Therapy: A Single-Institution Retrospective Analysis of 514 Patients. Cancers, 2019, 11, 1856.	1.7	15
359	Effectiveness of Firstâ€Line Bevacizumab in Metastatic Colorectal Cancer: The Observational Cohort Study GRETA. Oncologist, 2019, 24, 358-365.	1.9	17
360	Real-world use of bevacizumab in metastatic colorectal, metastatic breast, advanced ovarian and cervical cancer: a systematic literature review. Future Oncology, 2019, 15, 543-561.	1.1	10
361	Benefits of repeated resections for liver and lung metastases from colorectal cancer. Asian Journal of Surgery, 2020, 43, 102-109.	0.2	14
362	RAS and BRAF in the foreground for non-small cell lung cancer and colorectal cancer: Similarities and main differences for prognosis and therapies. Critical Reviews in Oncology/Hematology, 2020, 146, 102859.	2.0	12
364	Precision Approaches in the Management of Colorectal Cancer: Current Evidence and Latest Advancements towards Individualizing the Treatment. Cancers, 2020, 12, 3481.	1.7	9
365	Does the presence of an intact primary increase the risk of nonelective colorectal surgery in patients treated with bevacizumab?. Colorectal Disease, 2020, 22, 1974-1983.	0.7	0
366	Effectiveness of Combining Bevacizumab With First-Line Chemotherapy Regimens for Metastatic Colorectal Cancer in Real-World Practice. Clinical Colorectal Cancer, 2021, 20, 101-112.e6.	1.0	4
367	Chemotherapy and Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer. Journal of Clinical Medicine, 2020, 9, 4015.	1.0	7
368	Long noncoding RNA ARSR is associated with a poor prognosis in patients with colorectal cancer. Journal of Gene Medicine, 2020, 22, e3241.	1.4	5
369	Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan. Clinical Therapeutics, 2020, 42, 1361-1375.	1.1	7
370	Practice variation on hospital level in the systemic treatment of metastatic colorectal cancer in The Netherlands: a population-based study. Acta OncolÃ³gica, 2020, 59, 395-403.	0.8	6
371	Efficacy and Safety of Bevacizumab Combined With First-Line Chemotherapy in Elderly (â‰¥75 Years) Patients With Metastatic Colorectal Cancer: A Real-World Study. Clinical Colorectal Cancer, 2020, 19, e100-e109.	1.0	7
372	FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial. British Journal of Cancer, 2021, 124, 587-594.	2.9	79
373	Efficacy and Safety of Bevacizumab Plus Oxaliplatin- or Irinotecan-Based Doublet Backbone Chemotherapy as the First-Line Treatment of Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis. Drug Safety, 2021, 44, 29-40.	1.4	4

#	Article	IF	Citations
374	Markers of Sensitivity and Resistance to EGFR Inhibitors in Colorectal Cancer. , 2021, , 221-270.		0
375	Efficacy and safety of chemotherapy combined with bevacizumab in Chinese patients with metastatic colorectal cancer: A prospective, multicenter, observational, non-interventional phase IV trial. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2021, 33, 490-499.	0.7	5
376	GI Toxicities from Cancer Therapy. , 2021, , 341-379.		0
377	Optimal duration of therapy in the first line treatment of metastatic colorectal cancer: Single center experience. Vojnosanitetski Pregled, 2022, 79, 796-804.	0.1	2
378	A predictive model for early recurrence of colorectal-cancer liver metastases based on clinical parameters. Gastroenterology Report, 2021, 9, 241-251.	0.6	9
379	Doubling the Dose of Bevacizumab Beyond Progression in Metastatic Colorectal Cancerâ€"the Experience of a Tertiary Cancer Center. Frontiers in Pharmacology, 2021, 12, 487316.	1.6	2
380	Clinical Evaluation of Thirteen Patients with Acute Abdomen Receiving Bevacizumab. Japanese Journal of Gastroenterological Surgery, 2021, 54, 228-235.	0.0	0
381	Partnering bevacizumab with irinotecan as first line-therapy of metastatic colorectal cancer improves progression free survival-A retrospective analysis. PLoS ONE, 2021, 16, e0248922.	1.1	1
382	Management of colorectal cancer in the era of COVID-19: Challenges and suggestions. Science Progress, 2021, 104, 003685042110106.	1.0	12
383	A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer. Investigational New Drugs, 2021, 39, 1335-1347.	1.2	1
384	In vitro angiogenesis inhibition with selective compounds targeting the key glycolytic enzyme PFKFB3. Pharmacological Research, 2021, 168, 105592.	3.1	14
385	Management of Metastatic Colorectal Carcinoma in Older Adults: Balancing Risks and Benefits of Novel Therapies. Drugs and Aging, 2021, 38, 639-654.	1.3	1
386	Real-world Safety of Bevacizumab with First-line Combination Chemotherapy in Patients with Metastatic Colorectal Cancer: Population-based Retrospective Cohort Studies in Three Canadian Provinces. Clinical Oncology, 2022, 34, e7-e17.	0.6	7
387	Utility of exome sequencing in routine care for metastatic colorectal cancer. Molecular and Clinical Oncology, 2021, 15, 229.	0.4	1
388	Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group. Clinical Colorectal Cancer, 2021, 20, 245-255.	1.0	2
390	Markers to Predict the Efficacy of Bevacizumab in the Treatment of Metastatic Colorectal Cancer. Tumori, 2014, 100, 370-376.	0.6	5
391	The Facilitating Role of Chemotherapy in the Palliative Phase of Cancer: Qualitative Interviews with Advanced Cancer Patients. PLoS ONE, 2013, 8, e77959.	1.1	40
392	Determinants of Long-Term Outcome in Patients Undergoing Simultaneous Resection of Synchronous Colorectal Liver Metastases. PLoS ONE, 2014, 9, e105747.	1.1	23

#	Article	IF	Citations
393	Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience. Radiology and Oncology, 2016, 50, 226-231.	0.6	3
394	Markers to predict the efficacy of bevacizumab in the treatment of metastatic colorectal cancer. Tumori, 2014, 100, 370-6.	0.6	5
395	Clinical parameters to guide decision-making in elderly metastatic colorectal cancer patients treated with intensive cytotoxic and anti-angiogenic therapy. Oncotarget, 2017, 8, 37875-37883.	0.8	12
396	CXCR4 and CXCL12 Expression in Rectal Tumors of Stage IV Patients Before and After Local Radiotherapy and Systemic Neoadjuvant Treatment. Current Pharmaceutical Design, 2015, 21, 2276-2283.	0.9	15
397	Metastatic colorectal cancer: What about the primary?. Acta Chirurgica Iugoslavica, 2012, 59, 47-55.	0.0	2
398	The Role of Thermal Ablation for Colorectal Liver Metastases in the Era of Effective Chemotherapy. Thermal Medicine, 2010, 27, 1-8.	0.0	4
399	Multi-modality treatment of colorectal liver metastases. World Journal of Gastroenterology, 2012, 18, 16.	1.4	20
400	Angiogenic inhibitors for older patients with advanced colorectal cancer: Does the age hold the stage?. World Journal of Gastroenterology, 2013, 19, 2131.	1.4	5
401	Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study. World Journal of Gastroenterology, 2015, 21, 7281-7288.	1.4	10
402	Multisciplinary management of patients with liver metastasis from colorectal cancer. World Journal of Gastroenterology, 2016, 22, 7215.	1.4	67
404	Bilateral pneumothorax after bevacizumab-containing chemotherapy in fibrosarcoma. Journal of Thoracic Disease, 2012, 4, 229-31.	0.6	13
405	Hepatic imaging response to radioembolization with yttrium-90-labeled resin microspheres for tumor progression during systemic chemotherapy in patients with colorectal liver metastases. Journal of Gastrointestinal Oncology, 2015, 6, 594-604.	0.6	14
406	Current treatment options for patients with initially unresectable isolated colorectal liver metastases. World Journal of Clinical Oncology, 2016, 7, 9.	0.9	9
407	Treatment of Metastatic Colorectal Cancer With or Without Bevacizumab: Can the Neutrophil/Lymphocyte Ratio Predict the Efficiency of Bevacizumab?. Asian Pacific Journal of Cancer Prevention, 2014, 15, 4781-4786.	0.5	23
408	Mean Platelet Volume as a Prognostic Marker in Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Combined Chemotherapy. Asian Pacific Journal of Cancer Prevention, 2014, 15, 6421-6423.	0.5	41
409	Efficacy and Safety of Bevacizumab in Chinese Patients with Metastatic Colorectal Cancer. Asian Pacific Journal of Cancer Prevention, 2014, 15, 6559-6564.	0.5	5
410	XELOX Plus Bevacizumab vs. FOLFIRI Plus Bevacizumab Treatment for First-line Chemotherapy in Metastatic Colon Cancer: a Retrospective Study of the Anatolian Society of Medical Oncology. Asian Pacific Journal of Cancer Prevention, 2015, 15, 10375-10379.	0.5	3
411	Predictive Significance of VEGF and HIF-1Î± Expression in Patients with Metastatic Colorectal Cancer Receiving Chemotherapy Combinations with Bevacizumab. Asian Pacific Journal of Cancer Prevention, 2015, 16, 6149-6154.	0.5	16

#	Article	IF	Citations
412	Health-Related Quality of Life Analysis in Metastatic Colorectal Cancer Patients Treated by Second-Line Chemotherapy, Associated With Either Cetuximab or Bevacizumab: The PRODIGE 18 Randomized Phase II Study. Clinical Colorectal Cancer, 2022, 21, e49-e61.	1.0	5
414	Preoperation Chemotherapy. Updates in Surgery Series, 2011, , 75-100.	0.0	0
415	Targeting Angiogenesis in the Treatment of Hepatic Metastasis. Cancer Metastasis - Biology and Treatment, 2011, , 417-430.	0.1	0
416	Blood Pressure Elevation in Patients Undergoing FOLFOX / FOLFIRI Therapy. Iryo Yakugaku (Japanese) Tj ETQq1 1 0.784314 rgBT /Ove	0.0	0
417	Oesophago-Gastric Cancer. , 2012, , 221-244.		9
418	Induction Chemotherapy in Combination with Bevacizumab for Stage IV Lung Cancer: Report of a Curative Resection Case. Japanese Journal of Lung Cancer, 2012, 52, 913-918.	0.0	0
419	Irinotecan and Capecitabine (CAPIRI) Plus Bevacizumab in First-Line Treatment of Metastatic Colorectal Cancer. Cancer and Clinical Oncology, 2012, 1, .	0.2	0
420	Hypertension and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with Bevacizumab. Journal of Korean Society of Health-System Pharmacists, 2012, 29, 324-337.	0.1	1
421	Clinical Study of the Correlation between Histological Types and the Efficacy of mFOLFOX6 ^|^plusmn; Bevacizumab in Patients with Metastatic Colorectal Cancer. Nihon Daicho Komonbyo Gakkai Zasshi, 2013, 66, 80-85.	0.1	0
422	Bevacizumab Plus Chemotherapy as First-Line Treatment for Patients with Metastatic Colorectal Cancer: Results from a Spanish Observational Study. Journal of Analytical Oncology, 0, , .	0.1	0
423	Targeted Therapies in Older Patients with Metastatic Colorectal Cancer. , 2013, , 141-159.		0
424	A Potential Administration-time Dependent Effect of Bevacizumab in Improving Overall Survival and Increasing Metastasis in Metastatic Colorectal Cancer. Chemotherapy, 2013, 02, .	0.0	1
425	Team Approach for XELOX+Bevacizumab Therapy. Nihon Daicho Komonbyo Gakkai Zasshi, 2013, 66, 7-12.	0.1	0
426	Bowel Perforation Following Continuation of Bevacizumab Post Nasal Septal Perforationâ€•A Case Report. Case Reports in Clinical Medicine, 2014, 03, 319-321.	0.1	0
427	External Validation of a Nomogram Predicting Disease-free Survival after Curative Resection of Liver Metastasis from Colorectal Cancer. Japanese Journal of Gastroenterological Surgery, 2014, 47, 467-476.	0.0	1
428	Bevacizumab in Combination with FOLFIRI in the First-Line Treatment of Patients with Advanced Colorectal Cancer: A Single- Institution Experience. Journal of Analytical Oncology, 0, , .	0.1	0
429	Anti-angiogenic Therapies in Colorectal Cancer. , 2014, , 383-396.		0
430	A Single Case of Retroperitoneal Hematoma that Occurred During Bevacizumab Combination Chemotherapy for Advanced Rectal Cancer. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College) Tj ETQq1 1 0.784314 rgBT /	0.0	0

#	Article	IF	Citations
431	Adverse Effects of Bevacizumab During Treatment for Metastatic Colorectal Cancer. Journal of Analytical Oncology, 2015, 4, 24-29.	0.1	0
432	Colorectal liver metastases. , 2015, , 121-132.		0
433	Risk of Gastrointestinal Perforation in Patients with Metastatic Colorectal Cancer Receiving Bevacizumab. Japanese Journal of Gastroenterological Surgery, 2016, 49, 75-83.	0.0	2
434	Complications of palliative antiangiogenic therapy in patients with colorectal cancer. OnCOReview, 2016, 6, 0-0.	0.1	2
435	Cardiotoxicity: Hypertension. , 2017, , 163-174.		0
436	Systemic chemotherapy for hepatic colorectal cancer. , 2017, , 1488-1501.e5.		0
437	TARGETED THERAPY IN COMPREHENSIVE MANAGEMENT OF METASTATIC COLON CANCER. Russian Journal of Oncology, 2017, 22, 266-273.	0.1	0
438	GI Toxicities from Cancer Therapy. , 2020, , 1-39.		0
439	Sequencing of Systemic Chemotherapy for Unresectable CRLM. , 2020, , 297-312.		0
440	Mechanisms and anatomical risk factors of pneumothorax after Bevacizumab use: A case report. World Journal of Clinical Oncology, 2020, 11, 504-509.	0.9	3
441	Fluorescence Bioanalysis of Bevacizumab Using Pre-Column and Post-Column Derivatization â€“ Liquid Chromatography After Immunoaffinity Magnetic Purification. Chromatography, 2020, 41, 115-122.	0.8	2
442	SystemÄ±c Chemotherapy in Colorectal Cancer. , 2021, , 693-705.		0
443	Evaluating the treatment of metastatic colorectal cancer with monoclonal antibodies. Journal of Medicine and Life, 2012, 5, 168-72.	0.4	0
444	Alternate dosing of cetuximab for patients with metastatic colorectal cancer. Gastrointestinal Cancer Research: GCR, 2013, 6, 47-55.	0.8	8
445	Efficacy of chemotherapy plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: a meta-analysis and up-date. International Journal of Clinical and Experimental Medicine, 2015, 8, 1434-45.	1.3	10
446	Mechanism of action of the atypical retinoid ST1926 in colorectal cancer: DNA damage and DNA polymerase Î±. American Journal of Cancer Research, 2018, 8, 39-55.	1.4	11
447	Colorectal Carcinoma and Emerging Targeted Therapies. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2015, 32, 27S-31S.	0.6	0
448	Prognostic impact of and mutations in patients who underwent simultaneous resection for initially resectable colorectal liver metastases. International Journal of Clinical and Experimental Pathology, 2018, 11, 5981-5991.	0.5	1

#	Article	IF	Citations
449	Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management. ESMO Open, 2022, 7, 100338.	2.0	14
450	A Non-Interventional Multicenter Study of First-Line Bevacizumab in Combination with Chemotherapy in Patients with Metastatic Colorectal Cancer in Lebanon. Biologics: Targets and Therapy, 2022, Volume 16, 7-15.	3.0	0
451	Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. JNCI Cancer Spectrum, 2022, 6, .	1.4	3
452	Multicenter prospective observational post-approval study of safety and efficacy of bevacizumab (AvegraÂ®, BIOCAD) in patients with metastatic colorectal cancer in real world practice: APOLLON-11 and SOYUZ-APOLLON. Journal of Modern Oncology, 2021, 23, 695-702.	0.1	0
453	Thromboembolic Events Burden in Patients With Solid Tumors and Their Predisposing Factors. Cureus, 2022, 14, e23624.	0.2	0
454	Deep learning with whole slide images can improve the prognostic risk stratification with stage III colorectal cancer. Computer Methods and Programs in Biomedicine, 2022, 221, 106914.	2.6	16
455	Pneumothorax as a Complication of Bevacizumab-Containing Chemotherapy: A Systematic Review of Case Reports. Cureus, 2022, , .	0.2	2
456	Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM). ESMO Open, 2022, 7, 100567.	2.0	9
457	Clinical outcomes of targeted therapies in elderly patients aged â‰¥ 80 years with metastatic colorectal cancer. World Journal of Clinical Cases, 0, 10, 10066-10076.	0.3	0
458	Transplantation for Nonresectable Colorectal Liver Metastases: Long-Term Follow-Up of the First Prospective Pilot Study. Annals of Surgery, 2023, 278, 239-245.	2.1	22
459	Mortality of patients with metastatic colorectal cancer who received elective or emergent operation after exposure to bevacizumab: A nationwide database study. European Journal of Surgical Oncology, 2023, 49, 445-451.	0.5	1
460	Phase IIIb study of the bevacizumab biosimilar candidate BI 695502 plus mFOLFOX6 in metastatic colorectal cancer. Colorectal Cancer, 0, , .	0.8	0
462	Mechanisms of colorectal liver metastasis development. Cellular and Molecular Life Sciences, 2022, 79, .	2.4	7
463	Guidance for Treating the Older Adults with Colorectal Cancer. Current Treatment Options in Oncology, 2023, 24, 644-666.	1.3	0
464	Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice. Medicina (Lithuania), 2023, 59, 350.	0.8	3
465	Integrative analysis revealed that distinct cuprotosis patterns reshaped tumor microenvironment and responses to immunotherapy of colorectal cancer. Frontiers in Immunology, 0, 14, .	2.2	2
466	Using Bayesian Evidence Synthesis Methods to Incorporate Real-World Evidence in Surrogate Endpoint Evaluation. Medical Decision Making, 2023, 43, 539-552.	1.2	2